IA
NAMS icon

IFP Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

IFP Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102 Hold
3
– – ﹤0.01% 4953
2026
Q1 		$96 Hold
3
– – ﹤0.01% 4744
2025
Q4 		$105 Hold
3
– – ﹤0.01% 4578
2025
Q3 		$85 Hold
3
– – ﹤0.01% 4568
2025
Q2 		$54 Buy
3
+2
+200% +$36 ﹤0.01% 4793
2025
Q1 		$20 Hold
1
– – ﹤0.01% 4167
2024
Q4 		$26 Buy
+1
New +$21 ﹤0.01% 4414

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

IFP Advisors's NAMS Position: Q2 2026 in Review

IFP Advisors held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 3 shares worth $102. The position accounts for ﹤0.01% of the portfolio, ranked #4953.

IFP Advisors first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $105 in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • IFP Advisors held 3 shares of NewAmsterdam Pharma worth $102 as of Q2 2026.
  • IFP Advisors left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4953 holding.
  • IFP Advisors first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • IFP Advisors's NewAmsterdam Pharma position peaked at $105 in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.